- Types of Eczema
- Child Eczema
- Causes & Triggers
- Living with Eczema
- Eczema Products
- Get Involved
For the first time in decades, new drugs and therapies that may provide real relief for anyone living with eczema are close to being available. For many, this is a time of unprecedented hope. But what if there were a way to prevent the very first flare, to stop eczema from even starting? Frustrated by seeing patients with eczema […]
What you need to know Finding a treatment that works for your eczema or atopic dermatitis (AD) symptoms can feel like an endless cycle for some people. And it’s not just about finding the right medicine, but about getting it covered by your health plan as well. It’s hard enough when your eczema is flaring; […]
June 9, 2016 – On Monday, June 6, 2016 the pharmaceutical companies Regeneron and Sanofi, reported positive results for the Phase 3 the clinical trial of the new biologic drug, dupilumab, when used in conjunction with a topical corticosteroid by adults to treat moderate-to-severe atopic dermatitis (AD).
February 10, 2016 – In January, Anacor Pharmaceuticals, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical ointment, 2%.
July 10, 2015 – Eczema can be challenging any time of year. Here are some tips for managing eczema during the summer from people just like you, friends on NEA’s Facebook page.
NEA formed a Scientific Advisory Committee Task Force to conduct a systematic review of topical corticosteroid withdrawal/topical steroid addiction in patients with atopic dermatitis and other dermatoses, and created a NEA education announcement on Topical Steroid Addiction/Withdrawal.
March 10, 2015 – There seem to be three major reasons why patients seek alternative medicine for atopic dermatitis: First, we simply don’t yet have a cure for this disease. Second, we can’t yet clearly explain why this disease occurs. While doctors try hard to describe factors that play a role in atopic dermatitis, such as cytokines and inflammatory cells, we still can’t pinpoint the root of the disease. Third, the outcomes of conventional atopic dermatitis treatments are not always consistent, and sometimes they are perceived as being unsafe.
March 10, 2015 – On March 9, 2015, NEA CEO Julie Block, 13-year old eczema patient Isaiah, 17-year old eczema patient Gracie, and their parents were present at an important Food and Drug Administrative (FDA) hearing regarding the unmet medical need for atopic dermatitis therapies in pediatrics.
March 5, 2015 – Check out this NPR piece on an important new study about how eczema affects the lives of people who have it by NEA Scientific Advisory Committee member Jonathan Silverberg, MD. Data from this study demonstrates the burden of living with eczema, which helps further the case for more eczema research.
February 24, 2015 – Introduction of peanut products into the diets of infants at high risk of developing peanut allergy was safe and led to an 81 percent reduction in the subsequent development of the allergy, a clinical trial has found.